Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer—a prospective national multicentre study (EMIT-1)Hege O. Ohnstad, Bjørn Naume, Egil Støre Blix et al.|ESMO Open|2024Cited by 14
Current treatment landscape of HR+/HER2− advanced breast cancer in the Nordics: a modified Delphi studyJürgen Geisler, Sophie Yammeni, Cathrine Bergquist Fosskaug et al.|Acta Oncologica|2023Cited by 6
Cost-effectiveness of Prosigna for Adjuvant Treatment Decisions in Early Breast Cancer: Healthcare Sector and Societal PerspectivesLars Asphaug, Bjørn Naume, Lars A. Akslen et al.|Clinical Breast Cancer|2025Cited by 2